FDA Brief

Warning letters Drugs

FDA warning letter to

Vasyl Melnyk, M.D.

MediumIssued Dec 21, 2021Posted Jan 4, 2022Center for Drug Evaluation and Research | CDER

FDA warns Dr. Vasyl Melnyk that he lost required records for an investigational drug trial.

What happened

FDA inspected Dr. Melnyk’s clinical site from September 13 to September 14, 2021, under its Bioresearch Monitoring Program. FDA found he did not retain required study records for a protocol under an undecided Biologics License Application, including signed and dated informed consent forms, supporting data for 16 randomized subjects, and case report forms. The sponsor’s contract research organization noted records were missing on August 2, 2021, and Dr. Melnyk said he could not locate them.

What FDA found

  1. He failed to keep required clinical trial records for the required period.

    21 CFR 312.62(c)
  2. He failed to keep signed and dated informed consent forms for all randomized subjects.

    21 CFR 312.62(c)
  3. He failed to keep supporting data on medical history, eligibility, adverse events, concomitant medications, progress notes, and visit assessments for 16 randomized subjects.

    21 CFR 312.62(c)
  4. He failed to keep case report forms for all randomized subjects.

    21 CFR 312.62(c)

What FDA wants

Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations. If he believes he complied, include his reasoning and supporting information.

Who should pay attention

  • sponsors and CROs relying on trial data from this site
  • clinical investigators and site staff who keep study records
  • research sites that archive trial records

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Maria A. Carballosa, M.D.

    FDA warns Dr. Maria Carballosa over failure to retain clinical trial records for an investigational drug.

    Medium
  2. Amy Lightner, MD

    FDA warns sponsor-investigator Amy Lightner, MD over clinical trial violations, including dosing before eligibility tests and unreported serious adverse events.

    High risk
  3. Mehran Michael Bahrami, M.D.

    FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.

    High risk
  4. Konrad Rejdak, M.D., Ph.D.

    FDA warns Dr. Konrad Rejdak over clinical trial data integrity failures in a CIDP immune globulin study.

    Medium